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Abstract The energetics and kinetics of the interaction of
heparin with the Ca+2 and phospholipid binding protein annexin
V, was examined and the minimum oligosaccharide sequence
within heparin that binds annexin V was identified. Affinity
chromatography studies confirmed the Ca+2 dependence of this
binding interaction. Analysis of the data obtained from surface
plasmon resonance afforded a Kd ofV21 nM for the interaction
of annexin V with end-chain immobilized heparin and a Kd of
V49 nM for the interaction with end-chain immobilized heparan
sulfate. Isothermal titration calorimetry showed the minimum
annexin V binding oligosaccharide sequence within heparin
corresponds to an octasaccharide sequence. The Kd of a heparin
octasaccharide binding to annexin V wasV1 WM with a binding
stoichiometry of 1:1.
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1. Introduction
Annexins are a family of homologous proteins that are
widely distributed and ubiquitous in eukaryotes [1^5]. A dis-
tinctive feature of annexins is their calcium-dependent binding
to the surface of phospholipid membranes. The in vivo func-
tions of these proteins are unclear, but their close associations
with cell membranes suggest their involvement in various
processes, including: membrane tra⁄cking (e.g. exocytosis,
endocytosis), cytoskeletal-membrane interactions, signal
transduction, cell adhesion, and regulation of the activities
of ion channels and other membrane-bound proteins. Though
annexins were originally considered intracellular proteins,
many extracellular events are now proposed to be annexin-
mediated.
Annexins II and V have been studied most extensively in
terms of extracellular function. Annexin II acts as a co-recep-
tor for the plasminogen/tissue plasminogen activator [6], and
as a receptor for the human cytomegalovirus [7] and the ma-
trix protein, tenascin-C [8]. Annexin V, known in this context
as anchorin II, interacts strongly with collagen types II and X
[9]. A role in viral entry and infection by in£uenza [10] and
hepatitis B [11] viruses also has been demonstrated for annex-
in V. Several annexins, particularly annexin V, exhibit potent
anticoagulant activity in vitro.
Proteoglycans (i.e. macromolecules consisting of a protein
core and glycosaminoglycan side chains), which are found in
the extracellular matrix, on the cell surface and in secretory
granules are involved in a wide range of activities [12]. Some
of their functions are likely to depend on the direct interac-
tions between glycosaminoglycans (GAGs) and other mole-
cules [13]. Calcium-dependent lectin activity [14] and/or bind-
ing to speci¢c sialoglycoproteins and GAGs has been
identi¢ed in several annexins. The heparin binding properties
of annexin II tetramer have been characterized and a potential
heparin-binding site identi¢ed [15,16]. The binding of annex-
ins IV, V, and VI to GAGs, including heparin, heparan sul-
fate, or chondroitin sulfate, has been reported recently [17].
These studies have shown that the annexins express di¡erent
GAG preferences and that GAG binding may be calcium
dependent or independent. The present studies use a⁄nity
chromatography, isothermal titration calorimetry (ITC), and
surface plasmon resonance (SPR) to probe the energetics and
kinetics of the annexin V-heparin interaction. These studies
also enable the determination of the minimum oligosaccharide
sequence within heparin that binds to annexin V. Identi¢ca-
tion of a unique carbohydrate-binding site for annexin V will
provide a basis for understanding the mechanism of the inter-
action.
2. Materials and methods
Recombinant rat annexin V was prepared as described previously
[18]. Heparin, crude containing peptidoglycan (Mravg = 15 500; 150
U/mg), pharmaceutical (USP lyophilized, Mravg = 14 000; 177 U/
mg) and low molecular mass (LMW) (Mravg = 7000; 74 U/mg)
from porcine intestinal mucosa, sodium salts, were prepared by Celsus
Laboratories (Cincinnati, OH, USA). Peptidoglycan heparan sulfate
(Mravg = 11 000) was prepared from bovine kidney tissue in our labo-
ratory [19] by the method of Lyon and Gallagher [20]. A heparin-
derived octasaccharide was prepared by heparin lyase I (EC 4.2.2.7)
treatment of pharmaceutical heparin and puri¢ed to homogeneity by
gel permeation and strong anion exchange chromatography as previ-
ously described [21]. Biotin-x-hydrazide was from Calbiochem (La
Jolla, CA, USA), and biotin-LC-hydrazide, succinimidyl-6-(biotinami-
do) hexanoate (NHS-LC-biotin) and 1-ethyl-3-(dimethyl-aminoprop-
yl) carbodiimide hydrochloride (EDC) were from Pierce, (Rockford,
IL, USA). Guanidinium chloride, piperazine HCl, N-ethylmaleimide,
phenylmethylsulfonyl £uoride, trichloroacetic acid, deuterium oxide
(99.96 atom %) and chondroitinase ABC were obtained from Sigma
(St. Louis, MO, USA). Heparin lyases were from Siekagaku America,
(Rockville, MD, USA) and heparin disaccharide standards were from
Grampian Enzymes (Aberdeen, UK). Ultrapure urea was from Life
Technologies (Grand Island, NY, USA). Triton X-100, EDTA and
polyethylene glycol were from Fisher Scienti¢c (Fair Lawn, NJ,
USA). Proteinase K was from Boehringer Mannheim (Germany).
DEAE-Sephacel matrix was from Pharmacia Biotech (Uppsala, Swe-
den). All other reagents were analytical grade. Spectrophotometric
measurements were carried out on a Shimadzu model UV-2101PC
UV-vis spectrophotometer. ITC was performed on a Calorimetry Sci-
ences Corporation Model 4200 (Provo, UT, USA). SPR studies were
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done on a BIAcore 2000 instrument at the Biopolymer Facility of
Ohio State University (Columbus, OH, USA).
2.1. A⁄nity chromatography
A heparin-Sepharose column was equilibrated with annexin bu¡er
(50 mM HEPES at pH 7.4, containing 0.1 mM DTT). Annexin V (1.5
mg in 1 ml of annexin bu¡er) was loaded on the column and the
column was then washed with annexin bu¡er. The column was eluted
using a salt gradient (0.1 M^1.0 M) in the same bu¡er and 1 ml
fractions were collected. Protein was detected at 280 nm and salt
concentrations were determined by measuring the conductivity. This
experiment (loading, washing and salt gradient elution) was repeated
using an annexin bu¡er containing 5 mM CaCl2.
2.2. Isothermal titration calorimetry
Annexin V (50 WM, 1 ml) was prepared in 50 mM HEPES at pH
7.4, containing 0.1 mM DTT and 5 mM CaCl2. LMWH samples were
prepared in the same bu¡er at concentrations ranging from 600 to 155
WM. The sample cell was loaded with 1 ml of the protein sample and
the system was equilibrated for 15 min. LMW heparin was titrated
into the cell using a 100 Wl syringe (10 injections, 10 Wl each). Experi-
ments were performed at 25‡C. Calorimetry data were analyzed using
Origin 2.88 software. Experimental details and data processing relied
on previously described methods [22].
2.3. Immobilization of glycosaminoglycans
Peptidoglycan heparin and heparan sulfate were biotinylated in the
core peptide using NHS-LC-biotin to a¡ord reducing-end biotinylated
heparin and heparan sulfate. Pharmaceutical heparin was periodate
oxidized at residues within the polysaccharide chain and reacted with
biotin-hydrazide to a¡ord mid-chain biotinylated heparin [23]. A
streptavidin sensor surface (SA sensor chip, Pharmacia AB) was
pre-treated with three 5 Wl injections of 50 mM NaOH in 1 M
NaCl, to remove any non-speci¢cally bound contaminants. A 5 Wl
injection of reducing-end biotinylated heparin in HEPES running
bu¡er (HBS) (10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, pH
7.4 containing 0.005% (v/v) P-20 surfactant) was made followed by a
10 Wl injection of 2 M NaCl. The other three £ow cells of the sensor
chip were similarly treated to immobilize reducing-end biotinylated
heparan sulfate, mid-chain biotinylated heparin and bu¡er only to
serve as a control. An approximately 100 RU increase was detected
in each of the three glycosaminoglycan containing £ow cells when
compared to the control cell.
2.4. Kinetic measurement of annexin-glycosaminoglycan interactions
Typically, a 15 Wl injection of annexin (at a concentration range of
0.25^1.5 WM in annexin bu¡er containing 5 mM CaCl2) was made at
a £ow rate of 5 Wl/min. At the end of the sample plug, the same bu¡er
(without added annexin) was £owed past sensor the surface to allow
dissociation. After a suitable dissociation phase the sensor surface was
regenerated for the next annexin sample using a 10 Wl pulse of regen-
erating bu¡er (50 mM HEPES, pH 7.4 containing 0.1 mM DTT and
0.5 M NaCl). The same solution was £owed past all four sensor
surfaces in sequence and the response was monitored as a function
of time (sensorgram) at 25‡C. The control cell was used to subtract
the contribution of non-speci¢c interaction with the dextran matrix
itself. Kinetic parameters were evaluated using the BIA Evaluation
software according to the manufacturer’s methods by ¢rst evaluating
the dissociation rate constant kd using dR/dt =3kdR where R repre-
sents the sensor response. The association rate constant was deter-
mined from the slope of a plot of the observed association rate con-
stant ks as a function of ligand concentration, according to
ks = kd+kaC where ka is the association rate constant and C represents
the ligand concentration. The dissociation constant, Kd, was obtained
from the ratio of kd/ka.
2.5. NMR analysis
For 1H-NMR spectroscopy, approximately 1 mg of the heparin
octasaccharide sample was exchanged three times with 1 ml portions
of 2H2O and lyophilized. The thoroughly dried sample was redis-
solved in 0.7 ml 2H2O, and spectra were obtained using a UNITY-
500 spectrometer at the operating frequency of 500 MHz equipped
with a VXR 5000 computer system from Varian Instruments. Probe
temperature was 298 K.
3. Results
3.1. A⁄nity chromatography
Annexin V was loaded on the heparin-Sepharose column in
the absence and presence of calcium chloride. In the absence
of CaCl2 little if any protein bound to the column and most
protein was recovered in the wash. In the presence of CaCl2,
the protein bound to the column. Bound protein was eluted
from the column as soon as the salt gradient was started, i.e.
V0.1 M NaCl. This experiment con¢rmed the calcium-de-
pendence of the annexin V-heparin interaction. The concen-
tration of sodium chloride required to elute heparin-binding
proteins from heparin-Sepharose by disrupting ion-pairing in-
teraction is often used to estimate binding avidity [24,25].
However, in the present case, calcium binding and concom-
itant heparin binding to the protein cannot be di¡erentiated.
Potentially, either binding interaction can be antagonized by
increased ionic strength. Thus, an alternative method was
necessary to study heparin binding to annexin V.
3.2. Isothermal titration calorimetry
ITC is useful for measuring the energetics of heparin-pro-
tein binding [22] and thus, was applied to understand the
interaction of annexin V with heparin. The heat of interaction
measured by ITC can be used to calculate the Kd and n (the
number of ligand interactions per mol of macromolecule). The
titration between 50 WM annexin V and 156 WM LMW hep-
arin gave ¢tted heats of interaction of vH of 38.24 kcal/mol
yielding a Kd of 1.7 WM, and an n of approximately 3.7^4 mol
of annexin V per mol of LMW heparin (at 25‡C in annexin
bu¡er containing 5 mM CaCl2 at pH 7.4) (Fig. 1). Based on
the Mravg of 7000 determined for LMW heparin it has V20^
24 saccharide residues per GAG chain. Thus, the calculated
n value corresponds to a heparin-binding site for annexin V
consisting of 6^8 saccharide residues. To test this result, an
octasaccharide was prepared from heparin by partial depoly-
merization with heparin lyase I and puri¢ed to homogeneity
by gel permeation chromatography and strong anion ex-
change (SAX)-HPLC. Capillary and gel electrophoresis con-
¢rmed the purity of the octasaccharide to be s 95% [21]. The
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Fig. 1. Binding isotherm of the interaction between annexin V and
LMW heparin. 50 WM of annexin V was titrated against 156 WM of
LMW heparin at 25‡C in an annexin bu¡er containing 5 mM CaCl2
at pH = 7.4.
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primary structure of this octasaccharide was assigned using
1D 1H-NMR (Fig. 3). Isothermal titration calorimetry experi-
ments with the octasaccharide and annexin V a¡orded a Kd of
interaction of V1 WM and a binding stoichiometry of 1:1.
3.3. Kinetic measurement of annexin-glycosaminoglycan
interactions
Sensorgrams for the binding of annexin to the reducing-end
immobilized heparin are shown in Fig. 2. The initial part of
these curves represents a bu¡er £owing past the sensor sur-
face. The second and rising part of each curve corresponds to
the response of the sensor surface observed as a sample in-
jection volume £ows past the immobilized GAGs. The ¢nal
portion of the curves corresponds to the dissociation of bound
protein after the sample volume has ¢nished and the bu¡er
£ows past the sensor surface again. The dissociation rate con-
stant, kd, was evaluated from each trace and used to calculate
the observed association rate constant (ks). A plot of ks as a
function of ligand concentration yields a slope of the associ-
ation rate constant, ka. The ratio ka/kd generates the overall
association constant or dissociation constant. The binding
curves are relatively steep in the association phase (Fig. 2),
which is indicative of the high a⁄nity of annexin V for hep-
arin and a quick association step. The dissociation curves are
very gradual and shallow, which indicates that it is a tight
interaction. Kinetic analysis of the interaction between annex-
in and reducing-end immobilized heparin a¡orded a Ka value
of 4.9U107 M31 (Kd of 21 nM). Identical calculations for
mid-chain immobilized heparin and reducing-end immobilized
heparan sulfate yielded Ka (Kd) values of 2.0U107 M31 (Kd of
49 nM) and 2.4U107 M31 (Kd of 41 nM), respectively.
4. Discussion
The present studies a¡ord data on the energetics and ki-
netics of the calcium-dependent annexin V-heparin interac-
tion. Several lines of evidence indicate that the interaction is
not simply based on the a⁄nity of annexins for polyanions,
although the sulfate moieties are clearly important for binding
[17]. The speci¢city of the annexin V-heparin interaction is
demonstrated by the weak interactions of sucrose octasasul-
fate, as compared to a heparin-derived octasaccharide. A sim-
ilar conclusion is drawn from the observation that annexin V
binds heparin and heparan sulfate but not chondroitan sulfate
[17].
Waisman and coworkers have suggested, based on their
studies of annexin II, that heparin binds at a site that con-
forms to a consensus heparin binding sequence in domain 4
[15]. A similar binding site, consisting of Arg-283, Lys-284,
Arg-287, and Lys-288, can be predicted from the sequence of
annexin V. In terms of molecular structure, this region of the
protein is spatially distant from the annexin-membrane inter-
facial surface, which contains phospholipid and calcium bind-
ing sites. Instead, the consensus heparin binding sequences are
located on the opposite protein surface, which faces the cyto-
sol or extracellular milieu. Inspection of the rat annexin V
crystal structure [26,27] suggests the presence of a second
heparin binding sequence, Arg-205, Arg-206, and Lys-210 in
domain 3. The two putative heparin sites thus contain sym-
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Fig. 3. The 1D 1H-NMR of the octasaccharide identi¢ed as the
most probable annexin V binding oligosaccharide. The structure as
deduced by the NMR is also shown.
Fig. 2. SPR sensograms of annexin V- heparin (reducing-end biotinylated) interactions. Varying concentrations of annexin V (50, 30 and 10 Wg/
ml) were allowed to £ow over a BIAcore chip with reducing-end biotinylated heparin immobilized on the surface.
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metrical clusters of basic amino acids spaced 2^3 amino acids
apart, a pattern that is predicted to recognize heparin or
highly sulfated regions of heparan sulfate [13]. In annexin
V, the putative domain 4 site exhibits a classical B-B-X-X-
B-B pattern, while the domain 3 site lacks the fourth basic
residue. In the tertiary structure, each site presents the basic
residues on the same helical face (helices 3C or 4C, respec-
tively). Molecular modeling using a 12-saccharide heparin
molecule in a helical conformation ([28] ; Protein Data Bank
deposition number, 1HPN) suggests that an octasaccharide is
the smallest unit that would span the two predicted sites in
annexin V without signi¢cant rearrangement of the protein
structure. Thus the model agrees well with the experimental
data presented herein. Further studies on the interaction of
annexin V with heparin and other oligosaccharides are in
progress and should help elucidate the structural requirements
for binding and the mechanism of this interaction.
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